BioNxt Solutions

New era of chemotherapy

Ruhli

Invested

Community Contributor

Published

07 Oct 25

Views

215

07 Oct

CA$0.41

Ruhli's Fair Value

CA$1.20

65.4% undervalued

-23.1%

-3.5%

-23.1%

-3.5%

You can edit this narrative until Oct 8 12:50 PM. Then, changes will post as Updates.

Author's Valuation

CA$1.265.4% undervalued

Ruhli's Fair Value

Valuator

Company Info

Notes

Ruhli'sFair Value

CA$1.2

65.4% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

Forecast revenue growth rate

0.00%

Historical revenue growth rate

-29.04%

Pharma revenue growth rate

0.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.35%

Calculation

CA$10.38m

Earnings '30

24.62x

PE Ratio '30

CA$255.61m

Market Cap '30

CA$255.61m

Market Cap '30

159.71m

No. shares '30

CA$1.60

Share Price '30

CA$1.60 Share Price '30

Discounted to 2025 @ 5.97% p.a.

CA$1.20

Fair Value '25